Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 7,287 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 7,287 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. This trade represents a 27.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Joanne Quan also recently made the following trade(s):

• On Thursday, January 22nd, Joanne Quan sold 1,822 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $170,047.26.
• On Tuesday, January 20th, Joanne Quan sold 6,911 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $90.27, for a total transaction of $623,855.97.

Mirum Pharmaceuticals Trading Up 4.2%

Shares of NASDAQ MIRM traded up $3.91 on Tuesday, hitting $96.55. The company’s stock had a trading volume of 865,362 shares, compared to its average volume of 830,531. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. The stock has a 50 day moving average of $95.73 and a 200-day moving average of $80.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The business had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same period last year, the business earned $1.00 earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on MIRM. Morgan Stanley raised their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Citizens Jmp dropped their price objective on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday, February 26th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Royal Bank Of Canada reduced their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Emerald Advisers LLC boosted its holdings in shares of Mirum Pharmaceuticals by 20.9% during the third quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after purchasing an additional 63,834 shares during the last quarter. Candriam S.C.A. lifted its position in Mirum Pharmaceuticals by 8.0% during the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after buying an additional 30,021 shares during the period. TimesSquare Capital Management LLC acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $22,041,000. Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $808,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $503,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.